Docusol Paediatric Solution
Docusate Sodium Paediatric 12.5mg/5ml Oral Solution
5 ml of the solution contains 12.5 mg docusate sodium.
Excipient(s) with known effect:
Aspartame (E951) 15 mg per dose of syrup (5 mL)
Sorbitol 70% (E420) 1290 mg per dose of syrup (5 mL)
Methyl p-hydroxybenzoate (E218) 5 mg per dose of syrup (5 mL)
Propyl p-hydroxybenzoate (E216) 2.5 mg per dose of syrup (5 mL)
Sodium < 23 mg per dose of syrup (5 mL)
For full list of excipients, see section 6.1.
a) To prevent and treat chronic constipation
b) As an adjunct in abdominal radiological procedures
Children: one to two 5ml spoonfuls three times daily. Dilute the medicine in a glass of flavoured drink e.g. fruit juice or milk. Drink the diluted medicine within 30 minutes of preparation.
Infants (Over six months): one 5ml spoonful three times daily. Dilute the medicine in a glass of flavoured drink e.g. fruit juice or milk. Drink the diluted medicine within 30 minutes of preparation.
Adults: not appropriate for adults or elderly. For administration to adults use Docusol Adult Solution.
For barium meals: 30ml to be taken with meal.
Method of administration
Docusol solution should not be taken:
• by patients with a known hypersensitivity to docusate sodium or to any of the excipients listed in section 6.1.
• in the presence of abdominal pain, intestinal obstruction, nausea or if vomiting occurs.
Docusol Paediatric should not be given to infants under six months. Prolonged use can precipitate the onset of an atonic non-functioning colon and hypokalaemia.
Docusol Paediatric contains sorbitol.
This medicine contains 1290 mg sorbitol in each dose (5 mL). Sorbitol is a source of fructose. If the patient has an intolerance to some sugars or has herediatary fructose intolerance (HFI), a rare genetic disorder, the patient must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.
Docusol Paediatric contains 5 mg methyl p-hydroxybenzoate and 2.5 mg propyl p-hydroxybenzoate in each 5 mL dose.
May cause allergic reactions (possibly delayed).
Docusol Paediatric contains aspartame.
This medicine contains 15 mg of aspartame per dose (5 mL). Aspartame is a source of phenylalanine. It may be harmful to patients with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
Docusol Paediatric contains sodium.
This medicine contains less than 1 mmol sodium (23 mg) per 5 mL dose, that is to say essentially 'sodium-free'.
Docusol solution should not be taken concurrently with mineral oil. Anthraquinone derivatives should be taken in reduced doses, if administered with Docusol as their absorption is increased.
There is inadequate evidence of safety of the drug in human pregnancy, nor is there evidence from animal work that it is free from hazard, but it has been in wide use for many years without apparent ill consequence. Use in pregnancy only if the benefits outweigh the potential risks.
Docusate sodium is excreted in breast milk and should therefore be used with caution in lactating mothers.
Stimulant laxatives increase intestinal motility and often cause abdominal cramp. There have been spontaneous reports of burning sensation in mouth and throat following the use of Docusol Paediatric. Patients are advised to drink plenty of water or flavoured drink after taking the solution.
Reporting of suspected adverse reactions
Reporting suspected adverse reaction after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.
In rare cases of overdose excessive loss of water and electrolytes should be treated by encouraging the patient to drink plenty of fluid.
ATC code: A06AA02 Laxatives, softeners, emollients
Docusate sodium acts as a faecal softener by increasing the penetration of water and fats.
Docusate sodium exerts its effects by means of its physical surfactant properties. However, there is some evidence that it is absorbed from the gastrointestinal tract and excreted in bile.
Sorbitol (70%) (E420)
Methyl p-hydroxybenzoate (E218)
Propyl p-hydroxybenzoate (E216)
Sodium acid phosphate
Glass bottle with a plastic screw cap. Each bottle contains 100ml, 125ml or 300ml.
Not all pack sizes may be marketed.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
39 Mahoney Green
09/03/1998 / 13/07/2006